1046817-01-9

Usage

Explanation

Represents the chemical composition of the compound, consisting of 15 carbon, 25 hydrogen, 3 nitrogen, 3 oxygen, and 1 sulfur atoms.

Explanation

The compound serves as a key building block in the creation of different medications, including antihistamines and antiarrhythmics.

Explanation

The compound is derived from piperidine, which is a nitrogen-containing ring structure that provides the basis for its chemical properties and reactivity.

Explanation

The attachment of the ethylpyrimidin-2-yl group to the piperidin-4-yl part of the molecule enhances its pharmacological properties, making it more effective for drug development.

Explanation

The presence of the methanesulfonate group improves the compound's stability and solubility in various solvents, which is essential for its pharmaceutical applications.

Explanation

The compound plays a significant role in the development of various medications that provide therapeutic benefits to patients.

Pharmaceutical intermediate

Used in the synthesis of various drugs

Derivative of piperidine

Heterocyclic organic compound with a six-membered ring structure containing nitrogen atoms

Ethylpyrimidin-2-yl group

Added to the piperidin-4-yl moiety

Methanesulfonate group

Contributes to stability and solubility

Role in drug development

Crucial in the synthesis of medications with therapeutic benefits

Upstream product

• 111196-81-7 2-chloro-5-ethylpyrimidine 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 1001397-29-0 1-(5-ethyl-2-pyrimidinyl)-4-piperidinol 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 1190979-63-5 methyl 3-chloro-4-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yloxy)benzoate 
• 1190979-51-1 4-(3-chloro-4-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yloxy)benzyl)piperazine-1-carboxylate 
• 1190979-55-5 5-ethyl-2-(4-(4-((1-(methylsulfonyl)piperidin-4-yl)methyl)phenoxy)piperidin-1-yl)pyrimidine 
• 1190979-24-8 5-ethyl-2-(4-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenoxy)piperidin-1-yl)pyrimidine 
• 1392137-45-9 1-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yl)-5-(4-(methylsulfonyl)phenyl)-1H-indole 
• 1392137-52-8 3-chloro-1-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yl)-5-(4-(methylsulfonyl)phenyl)-1H-indole 
• 1190979-66-8 N-tert-butyl 4-(3-chloro-4-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yloxy)benzyl)-3-oxopiperazine-1-carboxylate 
• 1190979-62-4 1-(3-chloro-4-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yloxy)benzyl)-4-(methylsulfonyl)piperazin-2-one 
• 1190979-83-9 N-tert-butyl 3-(3-chloro-4-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yloxy)benzyloxy)azetidine-1-carboxylate 
• 1190979-68-0 2-(4-(2-chloro-4-((4-(methylsulfonyl)piperidin-1-yl)methyl)phenoxy)piperidin-1-yl)-5-ethylpyrimidine 
• 1190979-67-9 1-(3-chloro-4-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yloxy)benzyl)piperazin-2-one 
• 1190979-64-6 (3-chloro-4-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yloxy)phenyl)methanol 
• 1190979-65-7 2-(4-(2-chloro-4-(chloromethyl)phenoxy)piperidin-1-yl)-5-ethylpyrimidine 

Relevant academic research and scientific papers

BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS

The present invention provides a new class of bicyclic heteroaryl compounds represented by Formula (I), pharmaceutical compositions containing these compounds, and their use for modulating the activity of GPR119 in the treatment of metabolic disorders and complications thereof, as well as methods for the treatment of the metabolic disorders and complications thereof.

COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119; such as, but not limited to, diabetes, obesity and associated metabolic disorders. Formula (I) is a compound, in which A can have up to 2 ring -CH2- group substituted with -C(O)- and can be partially unsaturated with up to 2 double bonds; Wi and W2 are independently selected from CR10 and N; wherein R10 is selected from hydrogen and C1_6alkyl; Yi is selected from NRn, O and S; wherein Rn is selected from hydrogen and C1_ 6alkyl; Y2 and Y3 are independently selected from CH and N; Y4 is selected from CH2, OCH2 and NR15; wherein R15 is selected from hydrogen and C1_6alkyl; or the pharmaceutically acceptable salts thereof.

N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS

Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control.

COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.